Clover Biopharmaceuticals, Inc.

25 articles with Clover Biopharmaceuticals, Inc.

• Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

  12/4/2020

  Clover’s protein-based COVID-19 vaccine candidates adjuvanted with either GSK’s pandemic adjuvant system or Dynavax’s CpG 1018 plus alum induced strong neutralizing immune responses in 150 adult and elderly subjects from the Phase 1 clinical study.

• Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

  11/16/2020

  Cytiva provides FlexFactory™ bioprocessing upstream and downstream solutions for Clover to accelerate GMP facility development and shorten time to market

• 

  BioSpace Movers & Shakers, Oct. 2

  10/2/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Clover Biopharmaceuticals Announces Formation of a Global Scientific Advisory Board for its COVID-19 Vaccine Program

  9/25/2020

  Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced the formation of its Scientific Advisory Board (SAB) comprised of internationally-renowned experts in the vaccine industry, public health and policy making

• Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate

  9/25/2020

  Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge

• 

  Biopharma Update on the Novel Coronavirus: June 22

  6/22/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 22, 2020.

• Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

  3/24/2020

  Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) EMERYVILLE, Calif. and CHENGDU, China, March 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Clover Biopharmaceut

• 

  Biopharma Industry News for March 24: Update on the Novel Coronavirus

  3/24/2020

  A summary of daily biopharma industry news. Please check out stories that are trending on March 24, 2020.
• 

  Coronavirus Update: Vaccines Rushing into Clinical Trials

  3/5/2020

  As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.

• Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System

  2/24/2020

  Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate.

• Clover Successfully Produced 2019-nCoV Subunit Vaccine Candidate and Detected Cross-Reacting Antibodies from Sera of Multiple Infected Patients

  2/10/2020

  Clover Biopharmaceuticals announced that it has successfully produced its trimeric Spike-protein subunit vaccine candidate for 2019-nCoV via a mammalian cell expression system.

• Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)

  1/28/2020

  Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced that it has initiated development of a recombinant subunit vaccine for 2019-nCoV, the newly identified coronavirus that is believed to have originated from Wuhan, China.

• 

  Clinical Catch-Up: December 30, 2019 – January 2, 2020

  1/6/2020

  Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.

• Clover Biopharmaceuticals Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in China

  12/30/2019

  The Phase III, multi-center trial in China is designed to assess the efficacy, safety and pharmacokinetics of SCB-808 and originator drug Enbrel® in patients with ankylosing spondylitis (radiographic axial spondyloarthritis) via subcutaneous administration.

• Clover Biopharmaceuticals Completes $43 Million Series B Financing

  11/28/2019

  Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced the completion of a US$ 43 million Series B financing.

• Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)

  11/21/2019

  Clover Biopharmaceuticals announced that the first patient was dosed in a Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in Australia for the treatment of cancer patients with malignant pleural effusions.

• Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites

  9/29/2019

  Clover Biopharmaceuticals announced that the first patient was dosed in another Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, in China for the treatment of cancer patients with malignant ascites.

• Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis

  9/10/2019

  The Phase I, open-label, dose escalation trial in China is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of intraperitoneally administered SCB-313 as a single-agent for the treatment of peritoneal carcinomatosis.

• Clover Health Launches Clover Therapeutics, a New Research Subsidiary to Develop Treatment for Chronic Diseases

  7/10/2019

  Newly inked research collaboration and license agreement with Genentech aims to better understand the genetics of ocular diseases

• Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China

  5/7/2019

  A phase I clinical trial for malignant ascites is planned to initiate in China this year.